The "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2024)" has been officially announced. Merck's innovative drug Tabrecta hydrochloride has been officially included in the national medical insurance list for the treatment of locally advanced or metastatic non-small cell lung cancer in adults with exon 14 skipping mutations of mesenchymal-epithelial transition factor (MET). The new national medical insurance list will be officially implemented starting from January 1, 2025.
默克旗下创新药物盐酸特泊替尼纳入新版国家医保目录
Merck's innovative drug, Tabrecta hydrochloride, has been included in the new national medical insurance list.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated